We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Over 90 percent of clinical trials evaluating targeted cancer therapies or immunotherapies fell short in reporting adverse events in their publications — specifically in reporting recurrent or late toxicities, and detailing the duration of adverse events — according to researchers who studied 81 trials related to FDA-approved solid tumor treatments. Read More
Novartis will pay more than $35 million to settle off-label promotion charges when the company marketed its eczema cream, Elidel, for use on infants. Read More
Novartis is closing several of its research operations in Switzerland and China and cutting 175 jobs in an effort to centralize control of its drug discovery programs and contain costs. Read More
Amgen is contesting AbbVie’s allegations that its Humira biosimilar, Amjevita, infringes dozens of patents, saying AbbVie failed to raise at least six of those patents in regulatory submissions. Read More
Nippon Fine Chemical impeded a December 2015 inspection, the FDA said in a warning letter that claims employees blocked access to certain areas, refused to provide documents and prevented inspectors from taking photos. Read More
The UK’s price watchdog is not recommending reimbursement for Merck’s Keytruda for the treatment of advanced or metastatic lung cancer in patients who have had at least one previous chemotherapy regimen. Read More